Clinical trials: Neurodegenerative Disorders
Alzheimer's Disease
Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease
The purpose of this study was to see if taking lipoic acid plus omega-3 fatty acids (omega-3s) can slow the Alzheimer's disease (AD) process.
- Trial name
- NCT01058941
- Testing
- Lipoic acid and fish oil concentrate
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Oregon Health and Science University
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4)…
- Trial name
- NCT01892345
- Testing
- Eculizumab
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 143 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Spinal Muscular Atrophy
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
This study will test the safety, tolerability, and pharmacokinetics of escalating doses of nusinersen (ISIS 396443) administered into the spinal fluid either two or three times over the duration of the trial, in participants with…
- Trial name
- NCT01703988
- Testing
- Nusinersen
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Biogen
Alzheimer Disease
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested
- Trial name
- NCT03703856
- Testing
- Memantine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of California, San Diego
Alzheimer's Disease
Alzheimer's Prevention Through Exercise
The purpose of this study is to learn about the possible benefits of aerobic exercise in controlling or reducing the amount of amyloid present in the brain, reducing changes in brain structure that may lead to Alzheimer's Disease…
- Trial name
- APEx (NCT02000583)
- Testing
- Aerobic Exercise, Standard of Care
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Kansas Medical Center
Parkinson's Disease
Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
The aging Veteran population, together with high exposure to Agent Orange or other herbicides during military service, has made diseases such as Parkinson's disease (PD), currently affecting more than 80,000 Veterans, a major…
- Trial name
- Gen-Ex (NCT03607695)
- Testing
- Gait training
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- VA Office of Research and Development
Dementia With Lewy Bodies
Dementia With Lewy Bodies - Infinitome
Dementia with Lewy bodies (DLB) is the second most common cause of dementia and is associated with parkinsonism, hallucinations, and cognitive fluctuations.
- Trial name
- NCT04773041
- Testing
- Infinitome
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- HealthPartners Institute
Obstructive Sleep Apnea, Mild Cognitive Impairment
Mild Cognitive Impairment and Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) has been linked to increased risk for Alzheimer's disease (AD), but little prospective evidence exists on the effects of OSA treatment in preclinical AD.
- Trial name
- MEMORIES (NCT01482351)
- Testing
- CPAP adherence intervention, Attention control intervention
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- George Mason University
Neurodegenerative Disease, Weight Loss
Electronic-health Application To Measure Outcomes REmotely Clinical Trial
This is a phase II feasibility, safety, tolerability and preliminary efficacy study of an e-Health application versus in-person nutritional counseling to maintain or increase weight in patients with neurodegenerative diseases…
- Conditions
- Neurodegenerative Disease, Weight Loss, Amyotrophic Lateral Sclerosis, Parkinson's Disease
- Trial name
- EAT MORE (NCT02418546)
- Testing
- In-Person Nutritional Counseling by a Registered Dietitian, Nutritional counseling using an e-Health Application
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Massachusetts General Hospital
Dementia With Lewy Bodies
"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
This research study is to examine the effects of the study medication Armodafinil in patients with dementia with Lewy bodies (DLB).
- Trial name
- NCT01023672
- Testing
- Armodafinil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Parkinson Disease, Cognitive Dysfunction
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
- Trial name
- NCT05318937
- Testing
- SAGE-718
- Where
- 38 sites in United States
- Volunteers
- 86 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinsons Disease
Acupuncture for Fatigue in Parkinson's Disease
This is a single-center, double-blind, placebo-controlled trial to see if acupuncture can safety and effectively treat fatigue in Parkinson's Disease (PD).
- Trial name
- NCT01360229
- Testing
- Acupuncture, Acupuncture to treat fatigue in Parkinson disease
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- University of Colorado, Denver
Alzheimer Disease, Hypercholesterolemia
The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease
Some studies suggest that statin medications may be effective against Alzheimer's disease. However, this has not been proven. The purpose of this study is to evaluate the efficacy of pitavastatin in patients with mild to moderate…
- Trial name
- PIT-ROAD (NCT00548145)
- Testing
- Pitavastatin, cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Osaka University
Generalized Myasthenia Gravis
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)
- Trial name
- NCT03896295
- Testing
- M281
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 37 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Healthy Aging, Alzheimer Disease
Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease
The overall goal is to characterize the acute exercise response as it relates to brain glucose metabolism in aging and Alzheimer's Disease (AD).
- Trial name
- AEROBIC (NCT04299308)
- Testing
- Aerobic Exercise
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Parkinson Disease
Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days or more.
- Trial name
- NCT02305316
- Testing
- BIA 9-1067 non-micronized, BIA 9-1067 micronized
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Neurofibromatosis Type 1, Plexiform Neurofibroma
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib.
- Trial name
- NF108-BINI (NCT03231306)
- Testing
- Binimetinib
- Where
- 22 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Alzheimer's Disease
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01369225
- Testing
- AAB-003 (PF-05236812)
- Where
- 21 sites in United States, South Korea
- Volunteers
- 52 people
- Sponsor
- Pfizer
Myasthenia Gravis, Generalized
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis.
- Trial name
- RAISE (NCT04115293)
- Testing
- zilucoplan (RA101495)
- Where
- 77 sites in United States, Canada and 8 more
- Volunteers
- 174 people
- Sponsor
- Ra Pharmaceuticals, Inc.
Alzheimer Disease
Environmental Design for Behavioral Regulation in People With Dementia
Individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. Environmental features may be influential in behavioral regulation.
- Trial name
- NCT04555616
- Testing
- Standard Environmental Design, Individual Environmental Design
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Elizabeth K Rhodus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.